MEDTRONIC EXPANDS DIABETES SUPPORT PROGRAMS TO HELP CUSTOMERS LOSING INSURANCE COVERAGE DUE TO JOB LOSS AS A RESULT OF COVID-19
Medtronic Assurance Program Expands to Provide Access to Glucose Sensors and Insulin Pump Supplies at No Cost to Eligible Canadian Customers
BRAMPTON, Ontario – May 06, 2020 – Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an expansion of the Medtronic Assurance program with a new option to support current Canadian diabetes customers who have lost their private health insurance coverage due to COVID-19related job loss. Now, eligible customers can receive a 3-month supply of infusion sets, reservoirs and/or glucose sensors at no cost.
This new addition to the Medtronic Assurance program builds on the company’s holistic approach to ensuring that customers have continued access to diabetes technology and supplies. The Medtronic Assurance program has multiple options for customers in need that include flexible payment plans and payment deferrals for those who have experienced job loss.
“These are challenging times and the COVID-19 pandemic has had a significant impact in many ways on individuals and their families. Medtronic understands our products play an important role in the day-to-day management of diabetes. We have mobilized our teams to provide remote support, increased our online education resources, and introduced financial support options for people dealing with hardships,” said Laura Cameron, senior director of the Medtronic Diabetes and Consumer Care group in Canada. “We want our customers to know that we are here for them.”
Current customers who would like to learn more about the new Medtronic Assurance program and assess their eligibility can visit www.medtronicdiabetes.ca/covid19 or call Medtronic at 1-800-284.4416 and select Option 4 (Monday – Friday; 8:00 a.m. – 8:00 p.m. EST). Supporting documentation is required and terms and conditions apply.
About the Diabetes Group at Medtronic (www.medtronicdiabetes.ca)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
About Medtronic Canada ULC
Proudly serving Canadian healthcare for over 50 years, Medtronic Canada ULC (www.medtronic.ca), is a subsidiary of Medtronic plc, which is one of the world’s largest medical technology, services, and solutions companies — alleviating pain, restoring health, and extending life for millions of people around the world. Serving physicians, hospitals, and patients across the country, Medtronic Canada ULC is headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, and a Medtronic Resource Centre in Surrey, BC. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the impact of COVID-19 on our business, operations and production, as well as demand for our offerings, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation and general economic conditions and other risks and uncertainties described in the Company’s periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the Company, as filed with the U.S. Securities and Exchange Commission. In some cases, you can identify these statements by forward-looking words, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
